Injectable PrEP: Upcoming Webinar from The Choice Agenda

August 3, 2022

AIDS 2022 in Montreal just wrapped up, and stay tuned for our full summary soon. For now, though, a quick update on injectable cabotegravir for PrEP (CAB), which was a hot topic at the conference and the subject of next week’s Choice Agenda webinar.

  • New data from the HPTN 083 and 084 trials re-confirmed the safety and efficacy of CAB for PrEP;
  • WHO guidelines added injectable PrEP as an additional prevention option;
  • ViiV, the drug-maker of CAB for PrEP, and the Medicines Patent Pool announced an agreement to provide a voluntary license and begin the process of identifying generic manufacturers;
  • A new coalition convened by Unitaid, WHO, UNAIDS and the Global Fund, with AVAC serving as the secretariat, will collaborate with civil society, normative agencies, governments, and funders, in accelerating access to longer-acting PrEP; and
  • Advocacy and activism around global access to CAB included on-stage protests, meetings with key decision makers and many, many other discussions led by advocates and partners.
  • Join us Monday, 8 August at 9:00 ET / 15:00 SAST for our next The Choice Agenda webinar, Faster, Smarter and More Equitable – Accelerating Roll Out and Uptake of CAB for PrEP.

    title card for webinar

    As injectable cabotegravir (CAB) as PrEP begins to be introduced, what lessons have we learned from the first 10 years of oral PrEP implementation? How can the field do better with a new PrEP intervention that offers new opportunities and distinct challenges? These are the questions our panel will be discussing and more.

    • Rachel Baggaley, World Health Organization
    • Caroline Carnevale, New York Presbyterian Hospital
    • Monica Gandhi, University of California San Francisco
    • Mitchell Warren, AVAC
    • US cabotegravir (Apretude) user – RJ Mitchell